
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
These are very exciting times for dermatology. Basic research is being applied to the development of new and more effective biologics to treat some of the most challenging conditions, psoriasis among them.






